The
global Heparin
Market size
is expected to reach USD 7.4 billion by 2026, according to a new report by
Grand View Research, Inc. It is projected to register a CAGR of 1.6% during the
forecast period. Rising prevalence cardiovascular disorders, deep vein
thrombosis, and renal diseases among other chronic diseases is expected to
boost the growth.
According
to the data published in the American Heart Association, in 2018, approximately
92.1 million American adults were living with some form of cardiovascular
diseases. Coronary heart disease is one of the leading cause of deaths in U.S.
Furthermore, it was estimated that more than 23.6 million deaths will be
observed by 2030 due to cardiovascular diseases.
Increasing
demand for transfusion of blood, blood components, and plasma derivatives
during surgical procedures, treatment of infectious diseases, and increasing
survival rate are high impact rendering drivers for growth of the heparin
market during the forecast period. Increasing demand for RBCs and platelets by
various hospital divisions and clinics is expected to have a positive impact on
the growth.
Growing
geriatric population is anticipated to propel the market growth. According to
an article published in 2018 in the United States Census Bureau, it is
estimated that by 2035, population aged 65 years and above is expected to reach
78 million whereas children under the age of 18 may reach around 76.7million.
Rising
incidence of immunological diseases, thrombosis, and hemostasis is likely to
result in high demand for therapeutic plasma proteins. Manufacturing of plasma
proteins led to an increase in the demand for purified plasma, further expected
to fuel the market over the forecast period.
Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/heparin-market
Further key findings from the report suggest:
- Low
molecular weight heparin led the type segment in 2018 owing to its more
predictable anticoagulant effect
- In 2018,
ultra-low molecular weight heparin was estimated to be the fastest growing
segment, owing to commercialization of enhanced version of products with
improved pharmacological effects
- Subcutaneous
route of administration led the market in 2018 and is estimated to be the
fastest growing segment over the forecast period due to ease of
administration
- Coronary
artery disease was considered to be the largest application segment in 2018
and venous thromboembolism is projected to be the fastest growing segment
in near future
- In 2018,
outpatient led the end use segment and was estimated to register the
fastest growth in the forthcoming years
- North
America held the largest market share in 2018 owing to increasing
prevalence of cardiovascular disorders and sports injuries. Asia Pacific
is estimated to be the fastest growing segment over the forecast period
- Some of the
key companies operating in the heparin market are GlaxoSmithKline plc; Pfizer,
Inc.; Baxter; Leo Pharma A/S; Sanofi; Dr. Reddy’s Laboratories Ltd.; Aspen
Holdings; B. Braun Medical Inc.; Fresenius SE & Co. KGaA; and Teva
Pharmaceutical Industries Ltd
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment